Abstract:Ubiquitination, an important type of protein posttranslational modification (PTM), plays a crucial role in controlling substrate degradation and subsequently mediates the "quantity" and "quality" of various proteins, serving to ensure cell homeostasis and guarantee life activities. The regulation of ubiquitination is multifaceted and works not only at the transcriptional and posttranslational levels (phosphorylation, acetylation, methylation, etc.) but also at the protein level (activators or repressors). When regulatory mechanisms are aberrant, the altered biological processes may subsequently induce serious human diseases, especially various types of cancer. In tumorigenesis, the altered biological processes involve tumor metabolism, the immunological tumor microenvironment (TME), cancer stem cell (CSC) stemness and so on. With regard to tumor metabolism, the ubiquitination of some key proteins such as RagA, mTOR, PTEN, AKT, c-Myc and P53 significantly regulates the activity of the mTORC1, AMPK and PTEN-AKT signaling pathways. In addition, ubiquitination in the TLR, RLR and STING-dependent signaling pathways also modulates the TME. Moreover, the ubiquitination of core stem cell regulator triplets (Nanog, Oct4 and Sox2) and members of the Wnt and Hippo-YAP signaling pathways participates in the maintenance of CSC stemness. Based on the altered components, including the proteasome, E3 ligases, E1, E2 and deubiquitinases (DUBs), many molecular targeted drugs have been developed to combat cancer. Among them, small molecule inhibitors targeting the proteasome, such as bortezomib, carfilzomib, oprozomib and ixazomib, have achieved tangible success. In addition, MLN7243 and MLN4924 (targeting the E1 enzyme), Leucettamol A and CC0651 (targeting the E2 enzyme), nutlin and MI-219 (targeting the E3 enzyme), and compounds G5 and F6 (targeting DUB activity) have also shown potential in preclinical cancer treatment. In this review, we summarize the latest progress in understanding the substrates for ubiquitination and their special functions in tumor metabolism regulation, TME modulation and CSC stemness maintenance. Moreover, potential therapeutic targets for cancer are reviewed, as are the therapeutic effects of targeted drugs.

Targeting the Ubiquitin Pathway for Cancer Treatment

The role of ubiquitination in tumorigenesis and targeted drug discovery

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

Targeting E3 Ubiquitin Ligases for Cancer Therapy

Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy

Advancing targeted protein degradation for cancer therapy

Targeting the Ubiquitin Signaling Cascade in Tumor Microenvironment for Cancer Therapy

Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment

Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors

Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy

The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy

Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy

Targeting deubiquitinase USP28 for cancer therapy

E3 ubiquitin ligases as cancer targets and biomarkers.

The Skp2 Pathway: A Critical Target for Cancer Therapy

Protein degradation: expanding the toolbox to restrain cancer drug resistance

Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy